[1]Allers K, Hütter G, Hofmann J, et al., 2011. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood, 117(10):2791-2799.


[2]Bauer G, Anderson JS, 2014. Gene Therapy for HIV. Springer, New York, NY.
[3]Baumann M, 2016. CRISPR/Cas9 genome editing—new and old ethical issues arising from a revolutionary technology. Nanoethics, 10(2):139-159.
[4]de Miguel Beriain I, del Cano AMM, 2018. Chapter 12 Gene editing in human embryos. A comment on the ethical issues involved. In: Soniewicka M (Ed.), The Ethics of Reproductive Genetics: Between Utility, Principles, and Virtues. Springer, Cham, p.173-183.
[5]Dunbar CE, High KA, Joung JK, et al., 2018. Gene therapy comes of age. Science, 359(6372):eaan4672.


[6]Kim D, Bae S, Park J, et al., 2015. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods, 12(3):237-243.


[7]Li YJ, Han Y, Xie J, et al., 2014. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS, 28(4):521-530.


[8]Liang PP, Xu YW, Zhang XY, et al., 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell, 6(5):363-372.


[9]Liu SJ, Kong CJ, Wu J, et al., 2012. Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis. PLoS ONE, 7(4):e35020.


[10]Nie JB, Fitzgerald RP, 2016. Connecting the east and the west, the local and the universal: the methodological elements of a transcultural approach to bioethics. Kennedy Inst Ethics J, 26(3):219-247.


[11]Qiu RZ, 2016. Debating ethical issues in genome editing technology. Asian Bioeth Rev, 8(4):307-326.
[12]SinaTech, 2018. The first human immunodeficiency virus (HIV) immune gene-edited babies were born in China. https://tech.sina.cn/d/bk/2018-11-26/detail-ihmutuec3688779.d.html [Accessed on Nov. 26, 2018] (in Chinese).
[13]Tebas P, Stein D, Tang WW, et al., 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med, 370(10):901-910.


[14]Wang C, Zhai XM, Zhang XQ, et al., 2018. Gene-edited babies: Chinese academy of medical sciences’ response and action. Lancet, in press.
[15]Wu YX, Liang D, Wang YH, et al., 2013. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell, 13(6):659-662.


[16]Zhang XQ, 2016. Risk-benefit analysis of CRISPR-Cas germline editing clinical research on human embryos and its ethical governance. Sci Soc, 6(3):12-21 (in Chinese).
Open peer comments: Debate/Discuss/Question/Opinion
<1>